Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene ...

Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...

When a room of physicians at ASH 2024 was asked whether they had prescribed a gene therapy in a commercial context, only a ...

Long-term exposure to air pollution poses an increased risk of blood clots in deep veins, which can result in serious ...

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of ...

Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...

Wells Fargo has downgraded Editas (EDIT) to equal weight, citing concerns about the potential positioning of reni-cel. Read ...

Novel triple-drug therapies are showing promise for patients with various kinds of leukemia, researchers reported at the ...

Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

Novel triple-drug therapies are showing promise for patients with various kinds of leukemia, researchers reported at the American Society of Hematology meeting in San Diego.

Yi Lin, MD, PhD, hematologist and oncologist, Mayo Clinic, discusses the efficacy of ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor T-cell therapy vs standard treatments for patients ...